Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Nuvalent
AddedJul 6, 2026
UpdatedJul 6, 2026
Nuvalent

Nuvalent

Acquisition

Nuvalent develops targeted oncology therapies for clinically proven kinase targets.

HQ
Cambridge, MA, US
Founded
2017
Overview
M & A
Compare
Fundraising
Employees
News
Website

Nuvalent is a clinical-stage biopharmaceutical company developing small-molecule cancer therapies. Its programs focus on ROS1-positive and ALK-positive non-small cell lung cancer and other solid tumors.

The company uses structure-based drug design to build therapies intended to address resistance and improve target selectivity. Its investor materials describe lead programs zidesamtinib and neladalkib, with current clinical and regulatory activity in 2026.

Nuvalent - M & A Snapshot

Open M & A
  • GSK

    Acquired Nuvalent • $10.6B • Jun 9, 2026

Nuvalent - Similar Companies

NiKang Therapeutics logo

NiKang Therapeutics

Nested Therapeutics logo

Nested Therapeutics

nestedtx.com

Nexo Therapeutics logo

Nexo Therapeutics

nexotx.com

Viracta Therapeutics logo

Viracta Therapeutics

viracta.com

Revolution Medicines logo

Revolution Medicines

revmed.com

NuView Life Sciences logo

NuView Life Sciences

Novita Pharmaceuticals logo

Novita Pharmaceuticals

novita-pharm.com

NanoPharmaceuticals logo

NanoPharmaceuticals

Dual Therapeutics logo

Dual Therapeutics

Nivien Therapeutics logo

Nivien Therapeutics

NantBio logo

NantBio

Nurix logo

Nurix

nurixtx.com

NuvOx Pharma logo

NuvOx Pharma

nuvoxpharma.com

Traws Pharma logo

Traws Pharma

Navitor Pharmaceuticals logo

Navitor Pharmaceuticals

Nuvalent - Quick Facts

Who are Nuvalent's competitors?

Companies similar to Nuvalent include NiKang Therapeutics, Nested Therapeutics, Nexo Therapeutics and Viracta Therapeutics.

When was Nuvalent founded?

Nuvalent was founded in 2017.

Where is Nuvalent's headquarters located?

Nuvalent's headquarters is located in Cambridge, MA, US.

When was Nuvalent's last funding round?

Nuvalent's most recent funding round was for $10.6B (USD) in June 2026.

How much has Nuvalent raised to-date?

As of Jun 9, 2026, Nuvalent has raised a total of $10.6B (USD).

Nuvalent - Classification

Industry
  • Biotechnology
  • Oncology
  • Therapeutics
Ownership
  • Public Company
Technology
  • Chemistry
  • Precision Medicine
Geographic Exposure
  • Global
  • United States
Model
  • Clinical Stage Biopharma
Revenue
  • Pre-Revenue
Customer
  • Patients
Tags
  • Biopharmaceutical
  • Drug Development
  • Oncology
  • Precision Oncology
  • Small Molecule
Unique IDs
  • secCik: 0001861560
  • ticker: NUVL